PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Product offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights • Key buying criteria PART 05: Overview: Dermatophytic onychomycosis • Types of dermatophytic onychomycosis • Risk factors • Management • Epidemiology PART 06: Pipeline analysis • TDT 067 • P-3058 • MOB-015 • VT-1161 • Luliconazole solution, 10% • ME1111 • NP213 • HXP124 PART 07: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 08: Market segmentation by route of administration • Topical • Oral PART 09: Geographical segmentation • Global dermatophytic onychomycosis market by geographical segmentation 2015-2020 • Dermatophytic onychomycosis market in Americas • Dermatophytic onychomycosis market in EMEA • Dermatophytic onychomycosis market in APAC PART 10: Market drivers • Increase in R&D • Growing prevalence of dermatophytic onychomycosis • Unmet medical needs • Rise in prevalence of diabetes PART 11: Impact of drivers PART 12: Market challenges • Adverse effects and limited efficacy of drugs • Lack of awareness • Increased availability of generics and alternative therapies • Product recalls by US FDA PART 13: Impact of drivers and challenges PART 14: Market trends • Increased focus on combination therapies • Outsourcing of drugs manufacturing • Increase in strategic alliances among vendors • Incorporation of novel technology for product development PART 15: Vendor landscape • Competitive scenario • Anacor Pharmaceuticals • Galderma • Janssen Biotech • Novartis • Valeant Pharmaceuticals • Other prominent vendors PART 16: Appendix • List of abbreviations PART 17: Explore Technavio   List of Exhibits Exhibit 01: Key buying criteria for dermatophytic onychomycosis drugs Exhibit 02: Percentage of population undergoing treatment globally 2015 Exhibit 03: Pharmacological treatment for dermatophytic onychomycosis Exhibit 04: Treatment algorithm for dermatophytic onychomycosis Exhibit 05: Global dermatophytic onychomycosis therapeutics market overview Exhibit 06: Global dermatophytic onychomycosis market 2015-2020 ($ billions) Exhibit 07: Five forces analysis Exhibit 08: Comparison of activity of topical medications for onychomycosis Exhibit 09: Comparison of activity of oral medications for onychomycosis Exhibit 10: Global dermatophytic onychomycosis market segmentation by route of administration based on volume 2015 Exhibit 11: Dermatophytic onychomycosis market in US by route of administration based on revenue 2015 Exhibit 12: Segmentation of global dermatophytic onychomycosis market based on geography 2015 Exhibit 13: Global dermatophytic onychomycosis market revenue by geography 2015-2020 ($ billions) Exhibit 14: Dermatophytic onychomycosis market in Americas 2015-2020 ($ billions) Exhibit 15: Dermatophytic onychomycosis market in EMEA 2015-2020 ($ billions) Exhibit 16: Dermatophytic onychomycosis market in APAC 2015-2020 ($ billions) Exhibit 17: Global dermatophytic onychomycosis market: YoY growth and revenue based on geography 2015-2020 Exhibit 18: Comparison of onychomycosis prevalence with major diseases in US 2013 Exhibit 19: Impact of drivers Exhibit 20: Impact of drivers and challenges Exhibit 21: Anacor Pharmaceuticals: Key takeaways Exhibit 22: Galderma: Key takeaways Exhibit 23: Janssen Biotech: Key takeaways Exhibit 24: Novartis: Key takeaways Exhibit 25: Valeant Pharmaceuticals: Key takeaways

Anacor Pharmaceuticals, Galderma, Janssen Biotech, Novartis, Valeant Pharmaceuticals, Abeona Therapeutics, Allergan, Elorac, GlaxoSmithKline, Hexima, Hisamitsu Pharmaceutical, Mayne Pharma, MediQuest Therapeutics, Meiji Seika Pharma, Merz Pharma, Moberg Pharma, NanoBio, NovaBiotics, Nuvo Research, Pfizer, Polichem, Promius Pharma, Sanofi, Seren Pharmaceuticals, Taro Pharmaceutical, Topica Pharmaceuticals, Viamet Pharmaceuticals.